Safe use of tocilizumab in rheumatic patients with Kaposi's sarcoma
Dermatol Ther
.
2022 Nov;35(11):e15797.
doi: 10.1111/dth.15797.
Epub 2022 Sep 13.
Authors
Sarah Demouche
1
,
Pierre-Antoine Juge
2
,
Pierre Charles
3
,
Vincent Descamps
1
,
Khadija Benali
4
,
Florence Brunet-Possenti
1
Affiliations
1
Department of Dermatology, Hôpital Bichat, AP-HP, Paris, France.
2
Department of Rheumatology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France.
3
Department of Internal Medicine, Institut Mutualiste Montsouris, Université de Paris, Paris, France.
4
Department of Nuclear Medicine, Hôpital Bichat, AP-HP, Université de Paris, Paris, France.
PMID:
36038806
PMCID:
PMC9786762
DOI:
10.1111/dth.15797
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Sarcoma, Kaposi* / drug therapy
Substances
tocilizumab
Antibodies, Monoclonal, Humanized